Megan A. Clarke

Megan A. Clarke

Auto-generated profile, based on publicly available information

Megan A. Clarke

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Rockville, MD

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in International Journal of Cancer
Verified
Journal Article
Open access
ESElizabeth A. Stier
Elizabeth A. Stier
MCMegan A. Clarke
Megan A. Clarke
ADAshish A. Deshmukh
Ashish A. Deshmukh
NWNicolas Wentzensen
Nicolas Wentzensen
YLYuxin Liu
Yuxin Liu
NJNaomi Jay
Naomi Jay
The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high‐risk groups. Anal cancer incidence estimates by age among risk groups provided the basis to identify risk thresholds to recommend screening. Guided by risk thresholds, screening initiation at age 35 years was recommended for men who have sex with men (MSM) and transgender women (TW) with HIV. For other people with HIV and MSM and TW not with HIV, screening initiation at age 45 years was recommended. For solid organ transplant recipients, screening initiation beginning from 10 years post‐transplant was recommended. For persons with a history of vulvar precancer or cancer, screening initiation was recommended starting within 1 year of diagnosis of vulvar precancer or cancer. Persons aged ≥45 years with a history of cervical/vaginal HSIL or cancer, perianal warts, persistent (>1 year) cervical HPV16, or autoimmune conditions could be considered for screening with shared decision‐making, provided there is adequate capacity to perform diagnostic procedures (high‐resolution anoscopy [HRA]). Anal cytology, high‐risk (hr) human papillomavirus (HPV) testing (including genotyping for HPV16), and hrHPV‐cytology co‐testing are different strategies currently used for anal cancer screening that show acceptable performance. Thresholds for referral for HRA or follow‐up screening tests are delineated. These recommendations from IANS provide the basis to inform management of abnormal screening results, considering currently available screening tools. These guidelines provide a pivotal foundation to help generate consensus among providers and inform the introduction and implementation of risk‐targeted screening for anal cancer prevention.

1 August 2019 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MCMegan A. Clarke
Megan A. Clarke
SDSusan S. Devesa
Susan S. Devesa
SHSummer V. Harvey
Summer V. Harvey
NWNicolas Wentzensen
Nicolas Wentzensen
PURPOSE: Uterine corpus cancer incidence rates have been projected to increase, a prediction often attributed to the obesity epidemic. However, correct estimation of these rates requires accounting for hysterectomy prevalence, which varies by race, ethnicity, and region. Here, we evaluated recent trends in hysterectomy-corrected rates by race and ethnicity and histologic subtype and estimated differences in relative survival by race and ethnicity, subtype, and stage. METHODS: We estimated hysterectomy prevalence from the Behavioral Risk Factor Surveillance System. Hysterectomy-corrected age-standardized uterine corpus cancer incidence rates from 2000 to 2015 were calculated from the SEER 18 registries. Incidence rates and trends were estimated separately by race and ethnicity, region, and histologic subtype. Five-year relative survival rates were estimated by race and ethnicity, histologic subtype, and stage. RESULTS: Hysterectomy-corrected incidence rates of uterine corpus cancer were similar among non-Hispanic whites and blacks and lower among Hispanics and Asians/Pacific Islanders. Endometrioid carcinoma rates were highest in non-Hispanic whites, whereas nonendometrioid carcinoma and sarcoma rates were highest in non-Hispanic blacks. Hysterectomy-corrected uterine corpus cancer incidence increased among non-Hispanic whites from 2003 to 2015 and among non-Hispanic blacks, Hispanics, and Asians/Pacific Islanders from 2000 to 2015. Overall incidence rates among non-Hispanic blacks surpassed those of non-Hispanic whites in 2007. Endometrioid carcinoma rates rose among non-Hispanic blacks, Hispanics, and Asians/Pacific Islanders but were stable among non-Hispanic whites; however, nonendometrioid carcinoma rates rose significantly among all women. Non-Hispanic blacks had the lowest survival rates, irrespective of stage at diagnosis or histologic subtype. CONCLUSION: Among all women, rates of nonendometrioid subtypes have been rising rapidly. Our analysis shows profound racial differences and disparities indicated by higher rates of nonendometrioid subtypes and poorer survival among non-Hispanic black women.

25 June 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NWNicolas Wentzensen
Nicolas Wentzensen
BLBernd Lahrmann
Bernd Lahrmann
MCMegan A Clarke
Megan A Clarke
WKWalter Kinney
Walter Kinney
DTDiane Tokugawa
Diane Tokugawa
NGNiels Grabe
Niels Grabe
With the advent of primary human papillomavirus testing followed by cytology for cervical cancer screening, visual interpretation of cytology slides remains the last subjective analysis step and suffers from low sensitivity and reproducibility. We developed a cloud-based whole-slide imaging platform with a deep-learning classifier for p16/Ki-67 dual-stained (DS) slides trained on biopsy-based gold standards. We compared it with conventional Pap and manual DS in 3 epidemiological studies of cervical and anal precancers from Kaiser Permanente Northern California and the University of Oklahoma comprising 4253 patients. All statistical tests were 2-sided. In independent validation at Kaiser Permanente Northern California, artificial intelligence (AI)-based DS had lower positivity than cytology (P < .001) and manual DS (P < .001) with equal sensitivity and substantially higher specificity compared with both Pap (P < .001) and manual DS (P < .001), respectively. Compared with Pap, AI-based DS reduced referral to colposcopy by one-third (41.9% vs 60.1%, P < .001). At a higher cutoff, AI-based DS had similar performance to high-grade squamous intraepithelial lesions cytology, indicating a risk high enough to allow for immediate treatment. The classifier was robust, showing comparable performance in 2 cytology systems and in anal cytology. Automated DS evaluation removes the remaining subjective component from cervical cancer screening and delivers consistent quality for providers and patients. Moving from Pap to automated DS substantially reduces the number of colposcopies and also achieves excellent performance in a simulated fully vaccinated population. Through cloud-based implementation, this approach is globally accessible. Our results demonstrate that AI not only provides automation and objectivity but also delivers a substantial benefit for women by reduction of unnecessary colposcopies.

5 May 2022 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MCMegan A. Clarke
Megan A. Clarke
SDSusan S. Devesa
Susan S. Devesa
AHAnne Hammer
Anne Hammer
NWNicolas Wentzensen
Nicolas Wentzensen
Uterine cancer is the most common and second deadliest gynecologic cancer in the US, with 65 950 new cases and 12 550 deaths expected in 2022.1 Endometrioid carcinoma is the predominant histologic subtype, accounting for approximately 75% of all cases that are usually diagnosed at an early stage with good prognosis.2 These tumors are associated with obesity as well as hormonal and reproductive factors related to cumulative lifetime estrogen exposure.3,4 Nonendometrioid carcinomas account for approximately 15% to 20% of cases, have been described as estrogen independent,3,4 and are typically diagnosed at later stages with poorer prognosis.2,5 Uterine sarcomas are rare tumors that usually arise in the myometrium and are less well understood.2

10 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CCCamryn M. Cohen
Camryn M. Cohen
NWNicolas Wentzensen
Nicolas Wentzensen
PCPhilip E Castle
Philip E Castle
MSMark Schiffman
Mark Schiffman
RZRosemary Zuna
Rosemary Zuna
MCMegan A. Clarke
Megan A. Clarke
PURPOSE: We conducted an integrated population-based analysis of histologic subtype–specific cervical cancer incidence, survival, and incidence-based mortality by race and ethnicity, with correction for hysterectomy prevalence. METHODS: Using the SEER 21 and 18 registries, we selected primary cases of malignant cervical cancer diagnosed among women ≥ 15 years. We evaluated age-adjusted incidence rates among cases diagnosed between 2000 and 2018 (SEER21) and incidence-based mortality rates among deaths from 2005 to 2018 (SEER18), per 100,000 person-years. Rates were stratified by histologic subtype and race/ethnicity (incidence and mortality), and stage, age at diagnosis, and county-level measures of social determinants of health (incidence only). Incidence and mortality rates were corrected for hysterectomy using data from the Behavioral Risk Factor Surveillance System. We estimated 5-year relative survival by histologic subtype and stratified by stage at diagnosis. RESULTS: Incidence rates of cervical squamous cell carcinoma were highest in Black and Hispanic women, while incidence rates of cervical adenocarcinoma (ADC) were highest among Hispanic and White women, particularly for localized ADC. County-level income and education variables were inversely associated with squamous cell carcinoma incidence rates in all racial and ethnic groups but had less influence on ADC incidence rates. Black women had the highest overall mortality rates and lowest 5-year relative survival, irrespective of subtype and stage. Disparities in survival were particularly pronounced for Black women with regional and distant ADC, compared with other racial/ethnic groups. CONCLUSION: Although Black women are less likely to be diagnosed with ADC compared with all other racial/ethnic groups, they experience the highest mortality rates for this subtype, likely attributed to the poor survival observed for Black women with regional and distant ADC.

6 August 2022 in International Journal of Cancer
Verified
Journal Article
Closed access
MCMegan A. Clarke
Megan A. Clarke
ADAshish A. Deshmukh
Ashish A. Deshmukh
RSRyan Suk
Ryan Suk
JRJennifer Roberts
Jennifer Roberts
RGRichard Gilson
Richard Gilson
NWNicolas Wentzensen
Nicolas Wentzensen